| CCL2 produced by the glioma microenvironment is essential for the recruitment of regulatory T cells and myeloid-derived suppressor cells AL Chang, J Miska, DA Wainwright, M Dey, CV Rivetta, D Yu, D Kanojia, ... Cancer research 76 (19), 5671-5682, 2016 | 555 | 2016 |
| HIF-1α is a metabolic switch between glycolytic-driven migration and oxidative phosphorylation-driven immunosuppression of Tregs in glioblastoma J Miska, C Lee-Chang, A Rashidi, ME Muroski, AL Chang, ... Cell Reports 27 (1), 226-237. e4, 2019 | 251 | 2019 |
| Mitochondrial electron transport chain is necessary for NLRP3 inflammasome activation LK Billingham, JS Stoolman, K Vasan, AE Rodriguez, TA Poor, M Szibor, ... Nature immunology 23 (5), 692-704, 2022 | 148 | 2022 |
| Therapeutic targeting of tumor-associated myeloid cells synergizes with radiation therapy for glioblastoma P Zhang, J Miska, C Lee-Chang, A Rashidi, WK Panek, S An, M Zannikou, ... Proceedings of the National Academy of Sciences 116 (47), 23714-23723, 2019 | 123 | 2019 |
| Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial J Fares, AU Ahmed, IV Ulasov, AM Sonabend, J Miska, C Lee-Chang, ... The Lancet Oncology 22 (8), 1103-1114, 2021 | 115 | 2021 |
| Myeloid-derived suppressive cells promote B cell–mediated immunosuppression via transfer of PD-L1 in glioblastoma C Lee-Chang, A Rashidi, J Miska, P Zhang, KC Pituch, D Hou, T Xiao, ... Cancer immunology research 7 (12), 1928-1943, 2019 | 112 | 2019 |
| Activation of dopamine receptor 2 prompts transcriptomic and metabolic plasticity in glioblastoma SP Caragher, JM Shireman, M Huang, J Miska, F Atashi, S Baisiwala, ... Journal of Neuroscience 39 (11), 1982-1993, 2019 | 83 | 2019 |
| Sui generis: gene therapy and delivery systems for the treatment of glioblastoma JR Kane, J Miska, JS Young, D Kanojia, JW Kim, MS Lesniak Neuro-oncology 17 (suppl_2), ii24-ii36, 2015 | 78 | 2015 |
| Real-time immune cell interactions in target tissue during autoimmune-induced damage and graft tolerance J Miska, MH Abdulreda, P Devarajan, JB Lui, J Suzuki, A Pileggi, ... Journal of Experimental Medicine 211 (3), 441-456, 2014 | 77 | 2014 |
| FABP7 is a key metabolic regulator in HER2+ breast cancer brain metastasis A Cordero, D Kanojia, J Miska, WK Panek, A Xiao, Y Han, N Bonamici, ... Oncogene 38 (37), 6445-6460, 2019 | 72 | 2019 |
| Adoptive transfer of IL13Rα2-specific chimeric antigen receptor T cells creates a pro-inflammatory environment in glioblastoma KC Pituch, J Miska, G Krenciute, WK Panek, G Li, T Rodriguez-Cruz, ... Molecular therapy 26 (4), 986-995, 2018 | 69 | 2018 |
| OX40+ plasmacytoid dendritic cells in the tumor microenvironment promote antitumor immunity K Poropatich, D Dominguez, WC Chan, J Andrade, Y Zha, B Wray, ... The Journal of clinical investigation 130 (7), 3528-3542, 2020 | 67 | 2020 |
| STING agonist-loaded, CD47/PD-L1-targeting nanoparticles potentiate antitumor immunity and radiotherapy for glioblastoma P Zhang, A Rashidi, J Zhao, C Silvers, H Wang, B Castro, A Ellingwood, ... Nature communications 14 (1), 1610, 2023 | 62 | 2023 |
| βIII-tubulin regulates breast cancer metastases to the brain D Kanojia, RA Morshed, L Zhang, JM Miska, J Qiao, JW Kim, P Pytel, ... Molecular cancer therapeutics 14 (5), 1152-1161, 2015 | 62 | 2015 |
| Dendritic cell–based vaccines that utilize myeloid rather than plasmacytoid cells offer a superior survival advantage in malignant glioma M Dey, AL Chang, J Miska, DA Wainwright, AU Ahmed, IV Balyasnikova, ... The Journal of Immunology 195 (1), 367-376, 2015 | 61 | 2015 |
| Polyamines drive myeloid cell survival by buffering intracellular pH to promote immunosuppression in glioblastoma J Miska, A Rashidi, C Lee-Chang, P Gao, A Lopez-Rosas, P Zhang, ... Science Advances 7 (8), eabc8929, 2021 | 58 | 2021 |
| Repolarization of myeloid derived suppressor cells via magnetic nanoparticles to promote radiotherapy for glioma treatment C Wu, ME Muroski, J Miska, C Lee-Chang, Y Shen, A Rashidi, P Zhang, ... Nanomedicine: Nanotechnology, Biology and Medicine 16, 126-137, 2019 | 54 | 2019 |
| Activation of 4-1BBL+ B cells with CD40 agonism and IFNγ elicits potent immunity against glioblastoma C Lee-Chang, J Miska, D Hou, A Rashidi, P Zhang, RA Burga, ... Journal of Experimental Medicine 218 (1), e20200913, 2020 | 48 | 2020 |
| De novo purine biosynthesis is a major driver of chemoresistance in glioblastoma JM Shireman, F Atashi, G Lee, ES Ali, MR Saathoff, CH Park, S Savchuk, ... Brain 144 (4), 1230-1246, 2021 | 45 | 2021 |
| Anti-GITR therapy promotes immunity against malignant glioma in a murine model J Miska, A Rashidi, AL Chang, ME Muroski, Y Han, L Zhang, MS Lesniak Cancer Immunology, Immunotherapy 65, 1555-1567, 2016 | 44 | 2016 |
